
    
      A total of 140 subjects will be allocated into 2 groups of treatment; each group will consist
      of 70 subjects with the treatment regimens:

      Treatment I : 2 capsules of Omeprazole 20 mg, once daily and 1 placebo caplet of DLBS2411,
      twice daily Treatment II : 1 caplet of DLBS2411 250 mg, twice daily and 2 placebo capsules of
      omeprazole, once daily

      DLBS2411 will be administered twice daily at least 30 minutes before morning and evening
      meals, while omeprazole, once daily before morning meals, for 8 weeks of study period.

      The eligible subjects will receive either study medication (Treatment 1 or Treatment 2), for
      8 weeks of treatment; and will be instructed to come to the clinic every 4-week interval
      throughout the study period.

      Subjects will be evaluated for treatment efficacy at baseline and at interval of 4 weeks over
      the 8-week course of therapy.

      The safety profile of study medication other than vital signs and adverse event will be
      measured at baseline and end of study. Vital signs and adverse event will be measured at
      baseline and every follow-up visit including end of study.
    
  